Prostatic Neoplasms: Clinical Trials

60 trials for Prostatic Neoplasms, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

60 terminated. 60 Phase 3, 7 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 360Terminated 60
Phase 27Terminated 7

Follow Prostatic Neoplasms: new trials by email Literature Review of Prostatic Neoplasms trials Research Report on Prostatic Neoplasms

Trials (filtered) newest first · largest first

All 60 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
The Present Study Aims to Compare Patients Who Receive the Investigational Product (177Lu-DOTA-rosopatamab) Plus Standard of Care, in Comparison to Standard of Care Only
177Lu-DOTA-rosopatamb, Standard of Care - Metastatic Prostate Cancer
Phase 3TerminatedTelix Pharmaceuticals (Innovations) Pty Ltd162023-08-292026-02-20
Opioid-Free Pain Control Regimen Following Robotic Radical Prostatectomy
Oxycodone, Acetaminophen, Ketamine - Pain Management, Opioid Use
Phase 2 / Phase 3TerminatedWake Forest University Health Sciences582023-04-182026-06-15
Ga-68-PSMA-11 in Men With Prostate Cancer
Ga-68-PSMA-11 - Prostate Cancer, Prostate Adenocarcinoma
Phase 3TerminatedTimothy Hoffman382021-07-272023-02-24
Efficacy Evaluation of VERU-111 for mCRPC in Patients Who Have Failed at Least One Androgen Receptor Targeting Agent
VERU-111, Enzalutamide, Abiraterone - Metastatic Castration-resistant Prostate Cancer, Androgen Resistant Prostatic Cancer
Phase 3TerminatedVeru Inc.1052021-06-242024-02-05
Study of Pembrolizumab (MK-3475) Plus Docetaxel Versus Placebo Plus Docetaxel in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-921/KEYNOTE-921)-China Extension
Pembrolizumab, Docetaxel, Prednisone - Prostatic Neoplasms
Phase 3TerminatedMerck Sharp & Dohme LLC812020-09-232024-07-12
Randomized Trial of PSMA PET Scan Before Definitive Radiation Therapy for Prostate Cancer
Computed Tomography, Fluorine F 18 DCFPyL, Positron Emission Tomography - Stage I Prostate Cancer American Joint Committee on Cancer (AJCC) v8, Stage II Prostate Cancer AJCC v8
Phase 3TerminatedJonsson Comprehensive Cancer Center542020-08-142023-01-17
Patient Preference of Apalutamide Versus Enzalutamide in Patients With Recurrent or Metastatic Hormone-Sensitive Prostate Cancer
Apalutamide, Enzalutamide - Prostate Cancer
Phase 3TerminatedChinese University of Hong Kong742020-07-202026-10-27
Ferumoxtran-10-enhanced MRI in Prostate Cancer Patients
Ferrotran® (Ferumoxtran-10) - Prostate Cancer, Metastasis
Phase 3TerminatedSaving Patients' Lives Medical B.V.1722020-05-272026-04-28
Conventional Androgen Deprivation Therapy (ADT) With or Without Abiraterone Acetate + Prednisone and Apalutamide Following a Detectable PSA After Radiation and ADT
Prednisone, Apalutamide, Abiraterone Acetate - Prostate Cancer
Phase 3TerminatedDana-Farber Cancer Institute122020-04-202024-09-19
Extended Pelvic Lymph Node Dissection vs. no Pelvic Lymph Node Dissection at Radical Prostatectomy for intermediate-and High-risk Prostate Cancer
Radical prostatectomy (RP) followed by ePLND, Radical prostatectomy (RP) only - Prostate Cancer
Phase 3TerminatedSwiss Cancer Institute572019-08-272023-03-09
Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641)
Pembrolizumab, Enzalutamide, Placebo - Prostatic Neoplasms
Phase 3TerminatedMerck Sharp & Dohme LLC12442019-07-282026-09-28
Nutrition and Prostate Cancer
Fermented Soy, Placebo - Prostate Cancer
Phase 3TerminatedYale University192018-11-212021-05-26
Metformin in Patients Initiating ADT as Prevention and Intervention of Metabolic Syndrome
Metformin, Placebo Oral Tablet - Prostate Cancer, Metabolic Syndrome
Phase 3TerminatedCanadian Urologic Oncology Group1662018-07-122026-07-29
Trial of ADT and SBRT Versus SBRT for Intermediate Prostate Cancer
Degarelix, stereotactic body radiosurgery (SBRT) - Prostate Cancer
Phase 3TerminatedMemorial Sloan Kettering Cancer Center562017-03-282024-08-28
A Trial Comparing Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Advanced Prostate Cancer and Cardiovascular Disease
Degarelix, Leuprolide - Prostate Cancer
Phase 3TerminatedFerring Pharmaceuticals5452016-04-192022-06-29
Evaluating the Impact of Prostate Only Versus Pelvic Radiation for N+ Prostate Cancer.
radiotherapy - Prostate Cancer
Phase 3TerminatedUniversity Hospital, Ghent692016-04-012022-12-28
A Study of Galeterone Compared to Enzalutamide In Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic CRPC
Galeterone, Enzalutamide - Prostate Cancer
Phase 3TerminatedLTN PHARMACEUTICALS, INC.9532015-06-012023-03-15
Antibiotic Prophylaxis for HDR Brachytherapy in the Treatment of Prostate Cancer
Ciprofloxacin, Cefazolin - Prostate Cancer
Phase 3TerminatedCR-CSSS Champlain-Charles-Le Moyne1582015-02-102025-02-12
Prevention of Symptomatic Skeletal Events With Denosumab Administered Every 4 Weeks Versus Every 12 Weeks
Denosumab (reduced dosing), Denosumab (standard dosing) - Metastatic Breast Cancer, Metastatic Prostate Cancer
Phase 3TerminatedSwiss Cancer Institute13802014-07-162026-10-23
Study Of Tasquinimod In Asian Chemo-Naïve Patients With Metastatic Castrate-Resistant Prostate Cancer
Tasquinimod, Placebo - Prostatic Neoplasms, Castration-Resistant
Phase 3TerminatedIpsen1462014-01-012021-04-23

Showing 20 of 60. Sign in to see all of them.

Narrower conditions

Neoplasms (6)  ·  Neoplasm Metastasis (5)  ·  Lung Neoplasms (4)  ·  Breast Neoplasms (3)  ·  Erectile Dysfunction (2)  ·  Parkinson Disease 4, Autosomal Dominant Lewy Body (2)  ·  Prostatic Neoplasms, Castration-Resistant (2)  ·  Agnosia (1)  ·  Anemia (1)  ·  Bone Neoplasms (1)  ·  Brain Neoplasms (1)  ·  Colonic Neoplasms (1)  ·  Colorectal Neoplasms (1)  ·  Critical Illness (1)

Broader conditions

Genital Diseases (60)  ·  Genital Diseases, Male (60)  ·  Genital Neoplasms, Male (60)  ·  Male Urogenital Diseases (60)  ·  Neoplasms by Site (60)  ·  Prostatic Diseases (60)  ·  Urogenital Diseases (60)  ·  Urogenital Neoplasms (60)  ·  Neoplasms (54)  ·  Pathological Conditions, Signs and Symptoms (9)  ·  Pathologic Processes (6)  ·  Neoplastic Processes (5)  ·  Lung Diseases (4)  ·  Respiratory Tract Diseases (4)  ·  Respiratory Tract Neoplasms (4)

Interventions

Docetaxel (9)  ·  Leuprolide (9)  ·  Prednisone (8)  ·  Goserelin (7)  ·  bicalutamide (7)  ·  Radiotherapy (5)  ·  Zoledronic Acid (4)  ·  acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide (4)  ·  enzalutamide (4)  ·  Flutamide (3)  ·  Abiraterone Acetate (2)  ·  Calcium Dobesilate (2)  ·  Dexamethasone (2)  ·  Doxorubicin (2)  ·  Drug Therapy (2)

Sponsors

Ferring Pharmaceuticals (3)  ·  Ipsen (3)  ·  M.D. Anderson Cancer Center (3)  ·  Cell Genesys (2)  ·  European Organisation for Research and Treatment of Cancer - EORTC (2)  ·  Merck Sharp & Dohme LLC (2)  ·  Sanofi (2)  ·  Swiss Cancer Institute (2)  ·  Wake Forest University Health Sciences (2)  ·  Agennix (1)  ·  AstraZeneca (1)  ·  Auron Healthcare GmbH (1)  ·  Bracco Diagnostics, Inc (1)  ·  CR-CSSS Champlain-Charles-Le Moyne (1)  ·  Canadian Urologic Oncology Group (1)

Countries

United States (35)  ·  Canada (16)  ·  Germany (15)  ·  United Kingdom (13)  ·  Belgium (11)  ·  France (11)  ·  Poland (9)  ·  Czechia (8)  ·  Netherlands (8)  ·  Spain (8)  ·  Italy (7)  ·  Australia (6)  ·  Austria (5)  ·  Hungary (5)  ·  Slovakia (5)

Top investigators

Andrew K. Lee, MD (1)  ·  Anthony D'Amico, MD, PhD (1)  ·  Arnoud Templeton, MD (1)  ·  Ashok Hemal, MD (1)  ·  Barrett Childs, MD (1)  ·  Bernie Eigl, MD (1)  ·  Bobak Djavan, Prof (1)  ·  Carlos Vargas, MD (1)  ·  Charles L. Bennett, MD, PhD (1)  ·  Charles R Thomas, Jr, MD (1)

Results publications

PMID 34350976, PMID 15860850, PMID 16258090, PMID 22736604, PMID 23258223, PMID 23740935, PMID 24081940, PMID 24126237, PMID 24323035, PMID 24423462, PMID 26908063, PMID 31556911, PMID 32994091, PMID 33258687, PMID 33270906, PMID 33962579, PMID 34044584, PMID 34396210, PMID 34420143, PMID 34459214, PMID 35779938, PMID 38664019, PMID 38979716, PMID 40383193, PMID 40711960

NIH funding

P30CA016672 (2), 2005 (1), 2008 (1), 2014 (1), 2018 (1), P30CA012197 (1), U10CA045809 (1), U10CA081851 (1)